OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary
09 Novembre 2021 - 1:05PM
OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in
point-of-care and home diagnostic testing and sample collection
technologies, announced today that after almost 21 years of service
to the Company, Jack E. Jerrett is retiring as the Company’s Senior
Vice President, General Counsel, Chief Compliance Officer and
Secretary, effective as of December 31, 2021. Agnieszka M.
Gallagher, who most recently served as the Chief Ethics and
Compliance Officer at Alnylam Pharmaceuticals has been hired by the
Company to fill Jack’s roles as the new General Counsel, Chief
Compliance Officer and Secretary.
“Jack has been a stalwart and extremely
dedicated member of OraSure’s executive leadership team for over
two decades and his countless contributions to the Company’s growth
and development deserve our significant gratitude and
appreciation,” said Stephen S. Tang,
Ph.D., President and Chief Executive Officer
of OraSure Technologies. “While Jack’s leadership,
experience, and friendship will be sorely missed by the
organization, we are fortunate to have an outstanding replacement
with Aggie joining the Company and we are exceptionally pleased to
add her to the executive leadership team.”
Ms. Gallagher, age 48, brings to OraSure a
strong background with over two decades of legal and compliance
executive leadership experience. Most recently, Ms. Gallagher
served as the Chief Ethics and Compliance Officer for Alnylam
Pharmaceuticals, a large cap
biopharmaceutical company focused on RNAi therapeutics. Prior to
joining Alnylam, Ms. Gallagher was the General Counsel, Secretary,
and Chief Compliance Officer of ViiV Healthcare, overseeing a
multi-billion dollar annual business. Before ViiV Healthcare, Ms.
Gallagher served on GSK Vaccines executive team as Vice President,
Ethics and Compliance Officer, and prior to that she led GSK
Vaccines’ legal and antitrust work following its $5 billion
acquisition of Novartis Vaccines. Before joining GSK, Ms. Gallagher
served in leadership roles in the legal and compliance functions at
Sandoz (a Novartis Company), Medtronic Inc., and Pfizer
Inc.
Mrs. Gallagher holds a Juris Doctorate from
Rutgers Law School and a Bachelor of Arts Degree in Spanish from
Rutgers College.
About OraSure
TechnologiesOraSure Technologies empowers the global
community to improve health and wellness by providing access to
accurate, essential information. OraSure, together with its
wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis,
provides its customers with end-to-end solutions that encompass
tools, services and diagnostics. The OraSure family of companies is
a leader in the development, manufacture, and distribution of rapid
diagnostic tests, sample collection and stabilization devices, and
molecular services solutions designed to discover and detect
critical medical conditions. OraSure’s portfolio of products is
sold globally to clinical laboratories, hospitals, physician’s
offices, clinics, public health and community-based organizations,
research institutions, government agencies, pharma, commercial
entities and direct to consumers. For more information on OraSure
Technologies, please visit www.orasure.com.
Investor
Contact: |
Media
Contact: |
Scott Gleason |
Amy Koch |
Interim CFO & SVP Investor Relations & Corp.
Communications |
Sr. Mgr. Corporate Communications |
484-425-0588 |
484-523-1815 |
sgleason@orasure.com |
media@orasure.com |
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024